STRO logo

Sutro Biopharma Inc. (STRO)

$8.92

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on STRO

Market cap

$148084586

EPS

-12.46

P/E ratio

--

Price to sales

5.18

Dividend yield

--

Beta

1.563138

Price on STRO

Previous close

$9.32

Today's open

$9.36

Day's range

$8.65 - $9.57

52 week range

$7.15 - $43.85

Profile about STRO

CEO

Jane Chung

Employees

128

Headquarters

South San Francisco, CA

Exchange

NASDAQ Global Market

Shares outstanding

16601411

Issue type

Common Stock

STRO industries and sectors

Healthcare

Biotechnology & Life Sciences

News on STRO

Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

– STRO-004, TF-targeting ADC, Phase 1 STRIVE-01 study advancing; next clinical update and initiation of expansion cohorts planned first half of 2027 –

news source

GlobeNewsWire • Nov 12, 2026

news preview

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Here's Why Sutro Biopharma (STRO) is Poised for a Turnaround After Losing 34.2% in 4 Weeks

The heavy selling pressure might have exhausted for Sutro Biopharma (STRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Down 39.8% in 4 Weeks, Here's Why Sutro Biopharma (STRO) Looks Ripe for a Turnaround

Sutro Biopharma (STRO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

— STRO-006 is Sutro's second wholly-owned ADC to enter the clinic in less than one year —       — Initial clinical data expected in the second half of 2027 — SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors.

news source

GlobeNewsWire • Oct 21, 2026

news preview

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026.

news source

GlobeNewsWire • Sep 29, 2026

news preview

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – –   STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro's platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter ended June 30, 2026 and recent business highlights.

news source

GlobeNewsWire • Aug 12, 2026

news preview

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.

news source

Benzinga • Aug 12, 2026

news preview

Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 – – Continued advancement of wholly-owned pipeline, including ITGB6 ADC STRO-006 and dual-payload PTK7 program STRO-227, with IND submissions planned in 2026 – – First dual-payload iADC from Sutro's platform entered the clinic under Astellas collaboration; patient dosing underway – – Strong balance sheet with $202.6 million in cash, cash equivalents and marketable securities as of March 31, 2026; including gross proceeds from the recent capital raise, supporting operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2026 and recent business highlights.

news source

GlobeNewsWire • May 14, 2026

news preview

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

news source

Zacks Investment Research • Apr 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Sutro Biopharma Inc.

Open an M1 investment account to buy and sell Sutro Biopharma Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in STRO on M1